KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Zinc supplementation to improve prognosis in patients with compensated advanced chronic liver disease: a multicenter, randomized, double-blind, placebo-controlled clinical trial.

Juan Bañares, Laia Aceituno, Lourdes Ruiz-Ortega, Mònica Pons, Juan G Abraldes, Joan Genescà

Hepatol Commun 8(11) e0524

PMID39392768
PMCIDPMC11469812
DOI10.1097/HC9.0000000000000524
发表日期2024-10-11
摘要

摘要

Zinc homeostasis could play a role in compensated advanced chronic liver disease, and its supplementation has been linked to improvement in liver function, a decrease of hepatic complications, and reduction in HCC incidence. Compensated advanced chronic liver disease encompasses a heterogeneous group of patients with variable risks of clinically significant portal hypertension and clinical events. The ANTICIPATE model is a validated model for stratifying these risks. Our aim is to demonstrate that zinc administration can reduce the rate and risk of presenting clinical events (first decompensation, HCC, death, and liver transplantation). This study protocol describes an ongoing phase III, national, multicenter, randomized, double-blind clinical trial that will enroll 300 patients to receive either the trial treatment (zinc acexamate) or placebo. An inclusion period of 42 months is planned, with a minimum follow-up of 2 years. Our principal hypothesis is that zinc could modify the natural history of patients with compensated advanced chronic liver disease, with an overall improvement in prognosis.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。